![Western Blot: FoxC1 Antibody [NB100-1268] - Left- Significant upregulation of Foxc1 mRNA in Ezh2-/- Tet-ON PyVmT endpoint tumours compared to wild-type tumours. Right- Immunoblot of Ezh2+/+ or Ezh2-/- Tet-ON PyVmT endpoint tumours for Foxc1 and Ezh2 levels. Vinculin loading control. *p<0.05, two tailed t-test. Image collected and cropped by CiteAb from the following publication (nature.com/articles/s41467-018-04864-8), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/FoxC1-Antibody-Western-Blot-NB100-1268-img0018.jpg "Western Blot: FoxC1 Antibody [NB100-1268] - Left- Significant upregulation of Foxc1 mRNA in Ezh2-/- Tet-ON PyVmT endpoint tumours compared to wild-type tumours. Right- Immunoblot of Ezh2+/+ or Ezh2-/- Tet-ON PyVmT endpoint tumours for Foxc1 and Ezh2 levels. Vinculin loading control. *p<0.05, two tailed t-test. Image collected and cropped by CiteAb from the following publication (nature.com/articles/s41467-018-04864-8), licensed under a CC-BY license.")
| Reactivity | Hu, Mu, ZeSpecies Glossary |
| Applications | WB, ELISA, ICC/IF, IHC, ChIP, KD, KO |
| Clonality | Polyclonal |
| Host | Goat |
| Conjugate | Unconjugated |
| Concentration | 0.5 mg/ml |
| Immunogen | FoxC1 Antibody is made to a peptide with sequence RTSGAFVYDCSKF corresponding to C-Terminus according to NP_001444.2. |
| Localization | Nuclear |
| Isotype | IgG |
| Clonality | Polyclonal |
| Host | Goat |
| Gene | FOXC1 |
| Purity | Immunogen affinity purified |
| Innovator's Reward | Test in a species/application not listed above to receive a full credit towards a future purchase. |
| Dilutions |
|
||
| Application Notes | FoxC1 Antibody validated for ChIP from a verified customer review.A customer has reported positive results on human breast cancer cells (T47D). Use in IHC-P reactivity reported in (:29959321) . Use in IHC-Fr reported in scientific literature (PMID: 23862012). |
||
| Control |
|
||
| Publications |
|
| Storage | Store at -20C. Avoid freeze-thaw cycles. |
| Buffer | Tris saline (20 mM Tris pH 7.3, 150 mM NaCl), 0.5% BSA |
| Preservative | 0.02% Sodium Azide |
| Concentration | 0.5 mg/ml |
| Purity | Immunogen affinity purified |
![Immunohistochemistry ACE/CD143 Antibody [Unconjugated]](https://images.novusbio.com/images2/ACE_AF1513_Immunohistochemistry_6703.jpg)
![Western Blot ACE/CD143 Antibody [Unconjugated]](https://images.novusbio.com/images2/ACE_AF1513_Flow_Cytometry_20028.jpg)
![Simple Western ACE/CD143 Antibody [Unconjugated]](https://images.novusbio.com/images2/ACE_AF1513_Simple_Western_20109.jpg)
Secondary Antibodies |
Isotype Controls |
Research Areas for FoxC1 Antibody (NB100-1268)Find related products by research area.
|
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
![Immunocytochemistry/Immunofluorescence: FoxC1 Antibody [NB100-1268] - Paraformaldehyde fixed U2OS cells, permeabilized with 0.15% Triton. Primary antibody at 10 ug/mL, 1 hr incubation, followed by Alexa Fluor 488 secondary antibody at 2 ug/mL, showing nuclear and cytoplasmic staining. The nuclear stain is DAPI (blue). Negative control: Unimmunized goat IgG (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (2 ug/mL).](http://images.novusbio.com/fullsize/FoxC1-Antibody-Immunocytochemistry-Immunofluorescence-NB100-1268-img0015.jpg "Immunocytochemistry/Immunofluorescence: FoxC1 Antibody [NB100-1268] - Paraformaldehyde fixed U2OS cells, permeabilized with 0.15% Triton. Primary antibody at 10 ug/mL, 1 hr incubation, followed by Alexa Fluor 488 secondary antibody at 2 ug/mL, showing nuclear and cytoplasmic staining. The nuclear stain is DAPI (blue). Negative control: Unimmunized goat IgG (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (2 ug/mL).")
![Immunohistochemistry: FoxC1 Antibody [NB100-1268] - Representative images of formalin fixed paraffin-embedded tissue samples from human Luminal B tumours stained for FOXC1 and EZH2. Scale bar is 100um. Image collected and cropped by CiteAb from the following publication (nature.com/articles/s41467-018-04864-8), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/FoxC1-Antibody-Immunohistochemistry-NB100-1268-img0016.jpg "Immunohistochemistry: FoxC1 Antibody [NB100-1268] - Representative images of formalin fixed paraffin-embedded tissue samples from human Luminal B tumours stained for FOXC1 and EZH2. Scale bar is 100um. Image collected and cropped by CiteAb from the following publication (nature.com/articles/s41467-018-04864-8), licensed under a CC-BY license.")
![Flow Cytometry: FoxC1 Antibody [NB100-1268] - Paraformaldehyde fixed HEK293 cells (blue line), permeabilized with 0.5% Triton. Primary antibody at 10 ug/mL, 1 hr incubation, followed by Alexa Fluor 488 secondary antibody at 2 ug/mL. IgG control: Unimmunized goat IgG (black line) followed by Alexa Fluor 488 secondary antibody.](http://images.novusbio.com/fullsize/FoxC1-Antibody-Flow-Cytometry-NB100-1268-img0014.jpg "Flow Cytometry: FoxC1 Antibody [NB100-1268] - Paraformaldehyde fixed HEK293 cells (blue line), permeabilized with 0.5% Triton. Primary antibody at 10 ug/mL, 1 hr incubation, followed by Alexa Fluor 488 secondary antibody at 2 ug/mL. IgG control: Unimmunized goat IgG (black line) followed by Alexa Fluor 488 secondary antibody.")
![Knockdown Validated: FoxC1 Antibody [NB100-1268] - Left: Representative immunoblot showing Foxc1 expression in cells stably transduced with a control shRNA (shLacZ) or two independent shRNAs targeting Foxc1 and treated with DMSO or GSK-126 (2uM for 72h). a-Tubulin was used as a loading control. Image collected and cropped by CiteAb from the following publication (nature.com/articles/s41467-018-04864-8), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/FoxC1-Antibody-Knockdown-Validated-NB100-1268-img0017.jpg "Knockdown Validated: FoxC1 Antibody [NB100-1268] - Left: Representative immunoblot showing Foxc1 expression in cells stably transduced with a control shRNA (shLacZ) or two independent shRNAs targeting Foxc1 and treated with DMSO or GSK-126 (2uM for 72h). a-Tubulin was used as a loading control. Image collected and cropped by CiteAb from the following publication (nature.com/articles/s41467-018-04864-8), licensed under a CC-BY license.")
![Immunocytochemistry/ Immunofluorescence: FoxC1 Antibody [NB100-1268] - Breast Cancer subtype specificity of the EZH2/FOXC1 metastatic axis. a Representative images of formalin fixed paraffin-embedded tissue samples from human Luminal B tumours stained for FOXC1 & EZH2. Scale bar is 100 μm. b Significant negative correlation between FOXC1 transcript levels & EZH2 protein levels (Total intensity) quantified by immunofluorescence in human Luminal B patient samples (r = −0.52, p = 0.02). Eight different fields taken with a ×20 objective were quantified per sample. c Kaplan–Meier survival curve of relapse-free survival (RFS) of 1142 luminal B tumours with high or low FOXC1 (log rank p = 0.001). d Correlation between FOXC1 mRNA levels & the FOXC1 Signature in a cohort of 385 Luminal B patients from publicly available TCGA Breast Cancer data set. e Kaplan–Meier analysis of relapse-free survival of 1142 Luminal B tumours with high or low FOXC1 gene signature expression (log rank p = 0.0044). RFS relapse-free survival Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29959321), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-1268_goat-polyclonal-foxc1-antibody-310202415541964.jpg "Immunocytochemistry/ Immunofluorescence: FoxC1 Antibody [NB100-1268] - Breast Cancer subtype specificity of the EZH2/FOXC1 metastatic axis. a Representative images of formalin fixed paraffin-embedded tissue samples from human Luminal B tumours stained for FOXC1 & EZH2. Scale bar is 100 μm. b Significant negative correlation between FOXC1 transcript levels & EZH2 protein levels (Total intensity) quantified by immunofluorescence in human Luminal B patient samples (r = −0.52, p = 0.02). Eight different fields taken with a ×20 objective were quantified per sample. c Kaplan–Meier survival curve of relapse-free survival (RFS) of 1142 luminal B tumours with high or low FOXC1 (log rank p = 0.001). d Correlation between FOXC1 mRNA levels & the FOXC1 Signature in a cohort of 385 Luminal B patients from publicly available TCGA Breast Cancer data set. e Kaplan–Meier analysis of relapse-free survival of 1142 Luminal B tumours with high or low FOXC1 gene signature expression (log rank p = 0.0044). RFS relapse-free survival Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29959321), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![Western Blot: FoxC1 Antibody [NB100-1268] - Ectopic expression of Foxc1 alters invasion but not proliferation. a Transwell invasion assay of PyVmT cells expressing exogenous Foxc1 or GFP. Experiments were performed three times, & results are displayed relative to untreated parental cell. *p < 0.05, Student’s two tailed t-tests. b CyQUANT assay measuring cellular proliferation of PyVmT cells expressing exogenous GFP or Foxc1. R.F.U relative fluorescence units. Data were normalized to the fluorescence values at time = 0. c Enumeration of lung lesions following the injection of PyVmT cells expressing exogenous Foxc1 or GFP in the tail vein of athymic nude mice. *p < 0.05, Student’s two tailed t-tests. Scale bar is 5 mm. d Left: Representative immunoblot showing Foxc1 expression in cells stably transduced with a control shRNA (shLacZ) or two independent shRNAs targeting Foxc1 & treated with DMSO or GSK-126 (2 μM for 72 h). alpha -Tubulin was used as a loading control. Right: Transwell invasion assay of PyVmT cells infected with shRNA targeting LacZ (control) or two different sequences targeting Foxc1. Cells were pre-treated with DMSO or GSK-126 (2 μM) for 72 h & assayed for their capacity to invade through Matrigel. All assays were performed in triplicate. *p < 0.05, Student’s two tailed t-tests Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29959321), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-1268_goat-polyclonal-foxc1-antibody-3102024168211.jpg "Western Blot: FoxC1 Antibody [NB100-1268] - Ectopic expression of Foxc1 alters invasion but not proliferation. a Transwell invasion assay of PyVmT cells expressing exogenous Foxc1 or GFP. Experiments were performed three times, & results are displayed relative to untreated parental cell. *p < 0.05, Student’s two tailed t-tests. b CyQUANT assay measuring cellular proliferation of PyVmT cells expressing exogenous GFP or Foxc1. R.F.U relative fluorescence units. Data were normalized to the fluorescence values at time = 0. c Enumeration of lung lesions following the injection of PyVmT cells expressing exogenous Foxc1 or GFP in the tail vein of athymic nude mice. *p < 0.05, Student’s two tailed t-tests. Scale bar is 5 mm. d Left: Representative immunoblot showing Foxc1 expression in cells stably transduced with a control shRNA (shLacZ) or two independent shRNAs targeting Foxc1 & treated with DMSO or GSK-126 (2 μM for 72 h). alpha -Tubulin was used as a loading control. Right: Transwell invasion assay of PyVmT cells infected with shRNA targeting LacZ (control) or two different sequences targeting Foxc1. Cells were pre-treated with DMSO or GSK-126 (2 μM) for 72 h & assayed for their capacity to invade through Matrigel. All assays were performed in triplicate. *p < 0.05, Student’s two tailed t-tests Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29959321), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![Immunohistochemistry PITX2 Antibody [Unconjugated]](https://images.novusbio.com/images2/PITX2_AF7388_Immunohistochemistry_12162.jpg)
![N/A TIMP-1 [HRP]](https://images.novusbio.com/images2/DATA_TIMP1_DTM100_ELISA_847.jpg)
![N/A TIMP-1 [HRP]](https://images.novusbio.com/images2/TIMP-1_DTM100_ELISA_194.jpg)
![Western Blot Androgen R/NR3C4 [p Ser213, p Ser210] Antibody (156C135.2) - BSA Free](https://images.novusbio.com/images/Androgen-R-NR3C4-p-Ser213-p-Ser210-Antibody-156C135-2-Western-Blot-NB100-56603-img0004.jpg)
![N/A C-Reactive Protein/CRP [Biotin]](https://images.novusbio.com/images2/DATA_CReactive_Protein_DY1707_ELISA_1701.jpg)
![Simple Western Pax6 Antibody [Unconjugated]](https://images.novusbio.com/images2/Pax6_AF8150_Simple_Western_17126.jpg)
![Immunocytochemistry Pax6 Antibody [Unconjugated]](https://images.novusbio.com/images2/Pax6_AF8150_Immunocytochemistry_14427.jpg)
![Western Blot Pax6 Antibody [Unconjugated]](https://images.novusbio.com/images2/Pax6_AF8150_Western_Blot_14743.jpg)
![Bioactivity CTLA-4 [Unconjugated]](https://images.novusbio.com/images2/CTLA4_7268CT_2293.jpg)
![Western Blot Catalase Antibody [Unconjugated]](https://images.novusbio.com/images2/Catalase_AF3398_Western_Blot_5287.jpg)
![Simple Western Catalase Antibody [Unconjugated]](https://images.novusbio.com/images2/Catalase_AF3398_Simple_Western_16990.jpg)
![Knockout Validated Catalase Antibody [Unconjugated]](https://images.novusbio.com/images2/Catalase_AF3398_Knockout_Validated_24032.jpg)
